文献速递血栓与止血

静脉血栓栓塞症合并易栓症患者使用直接口服抗凝药:一项系统评价与荟萃分析

Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2019-02-25

该系统评价通过检索MEDLINE、Cochrane图书馆和Clinicaltrials.gov纳入10项研究,其中8项(1994例易栓症患者)进入随机效应荟萃分析。结果显示,易栓症患者使用直接口服抗凝药(DOAC)与维生素K拮抗剂(VKA)相比,静脉血栓栓塞症(VTE)复发率和大出血/临床相关非大出血事件率相似,VTE复发率和大出血/临床相关非大出血事件率均低且可比,提示DOAC是该人群的合适治疗选择。

要点

  • 在1994例易栓症患者中,DOAC与VKA的VTE复发率相似(RR 0.70,95%CI 0.34-1.44)。
  • 大出血/临床相关非大出血事件率在DOAC与VKA间相似(RR 0.92,95%CI 0.62-1.36)。
  • 因数据有限,尚不清楚结果是否适用于高危抗磷脂综合征、罕见易栓症或阿哌沙班。

核心结论

  • 各种易栓症患者接受DOAC或VKA治疗时,VTE复发率和出血事件率均低且可比,提示DOAC是该人群的合适治疗选择。
  • 由于数据有限,尚不清楚这些发现是否适用于高危抗磷脂综合征、罕见易栓症或阿哌沙班的使用。

研究设计与样本

  • 通过全面检索MEDLINE、Cochrane图书馆和Clinicaltrials.gov,识别出10项合格研究,其中8项报告1994例易栓症患者数据并纳入随机效应荟萃分析。
  • 合格研究为比较DOAC与维生素K拮抗剂(VKA)在VTE患者(包括易栓症患者)中的2至3期随机对照试验。

主要发现

  • 纳入荟萃分析的8项研究中,4项评估利伐沙班,3项评估达比加群,1项评估艾多沙班;未获得阿哌沙班使用的结果。
  • 易栓症患者中,DOAC组与VKA组相比,VTE复发率相似(RR 0.70;95%CI 0.34-1.44;I2=0%)。
  • 易栓症患者中,DOAC组与VKA组相比,大出血/临床相关非大出血事件率相似(RR 0.92;95%CI 0.62-1.36;I2=23%)。
  • 无已知易栓症患者中,VTE复发率(RR 1.02;95%CI 0.80-1.30;I2=46%)和大出血/临床相关非大出血事件率(RR 0.72;95%CI 0.57-0.90;I2=84%)的结果与易栓症患者相当。

局限性

  • 由于数据有限,尚不清楚这些发现是否适用于高危抗磷脂综合征、罕见易栓症或阿哌沙班的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials We investigated direct oral anticoagulant (DOAC) use in venous thromboembolism and thrombophilia. A comprehensive search identified 10 studies, 8 of which were included in a meta-analysis. DOACs were overall safe and effective in patients with venous thromboembolism and thrombophilia. Efficacy/safety of DOACs was maintained in low-risk antiphospholipid syndrome patient subgroup. SUMMARY: Background Direct oral anticoagulants (DOACs) are increasingly used in acute and long-term treatment of venous thromboembolism (VTE). However, their role in management of thrombophilia-associated VTE is controversial. Methods Through a comprehensive search on MEDLINE, Cochrane Library, and Clinicaltrials.gov, we identified 10 eligible studies, 8 of which reporting data on 1994 thrombophilia patients were included in a random-effects meta-analysis. Eligible studies were phase 2 to 3 randomized controlled trials comparing DOACs to vitamin K antagonists (VKAs) in patients with VTE, including those with thrombophilia. Results Of eight studies included in meta-analysis, four evaluated rivaroxaban, three dabigatran, and one edoxaban. No results could be obtained on apixaban use. The rates of VTE recurrence (RR, 0.70; 95% CI, 0.34-1.44; I2 = 0%) and major/clinically relevant non-major bleeding events (RR, 0.92; 95% CI, 0.62-1.36; I2 = 23%) were similar between thrombophilia patients treated with DOACs compared to VKAs. Results were comparable to findings in patients without known thrombophilia: RR, 1.02; 95% CI, 0.80-1.30; I2 = 46% for VTE recurrence and RR, 0.72; 95% CI, 0.57-0.90; I2 = 84% for major/clinically relevant non-major bleeding events. Conclusions Rates of VTE recurrence and bleeding events were both low and comparable in patients with various thrombophilias receiving either treatment, suggesting that DOACs are an appropriate treatment option in this population. Due to limited data, it is unclear whether these findings apply to specific subgroups such as high-risk antiphospholipid syndrome, uncommon thrombophilias, or the use of apixaban.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Elsebaie MAT, van Es N, Langston A, et al. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost. 2019. PMID: 30690830. doi:10.1111/jth.14398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。